On Tuesday, Shares of Oracle Corporation (NYSE:ORCL), gained 0.14% to $35.49.
Oracle Corporation - Emerging biopharmaceutical organizations face a growing number of regulatory requirements and, due to raised competition, acute pressure to speed time to market. Recently, Oracle Health Sciences declared that 93 of these emerging biopharma organizations worldwide have become new customers in the past year, adopting Oracle Health Sciences solutions to succeed in this rapidly evolving market and deliver drugs to patients faster.
Biopharmaceutical organizations, counting sponsors such as Accera and NewLink Genetics and contract research organizations (CROs) FMD K&L and 4C Pharma Solutions, selected Oracle Health Sciences solutions to manage their end-to-end clinical trial processes, boost clinical development productivity, facilitate compliance, and build scalable, affordable platforms for growth.
With the robust functionality of the Oracle Health Sciences suite of industry-leading cloud solutions such as Oracle Health Sciences InForm, Oracle Health Sciences IRT, Oracle Argus, Oracle’s Siebel Clinical Trial Administration System, and Oracle Health Sciences ClearTrial Plan and Source Enterprise Edition Cloud Service, these emerging organizations can now optimize productivity and navigate complex regulatory compliance requirements with ease.
Oracle Corporation (Oracle) is a provider of enterprise software and computer hardware products, and services. The Company’s offerings include Oracle database and middleware software, application software, cloud infrastructure, hardware systems including computer server, storage and networking products, and related services.
Shares of Mylan NV (NASDAQ:MYL), declined -2.59% to $39.80, during its last trading session.
Mylan believes that the Perrigo suit filed in Israel recently is entirely without merit and that Mylan’s offer in Israel is valid and proper in all respects.
With that said, Perrigo’s efforts are entirely futile, as all Perrigo shareholders—institutional and retail, counting those in Israel—have always been free to switch their holdings at any time from the Tel Aviv Stock Exchange (TASE) to the New York Stock Exchange (“NYSE”), through a simple, fully automated, well-established system by notifying their broker. As a result, shareholders can take part fully in Mylan’s compelling offer without regard to any lawsuits in Israel or any other frustrating actions pursued by Perrigo in Israel.
Further, as Mylan has formerly stated publicly, it has been our intent and desire to list Mylan’s shares on the TASE to maintain liquidity in Israel for the convenience of those shareholders in Israel who prefer to trade on the TASE, and Mylan is already well-advanced in the process of submitting its application to the TASE and the Israel Securities Authority, and is committed to ongoing to work closely with these parties to complete this process.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty.
Shares of Boston Scientific Corporation (NYSE:BSX), inclined 0.76% to $16.00, during its last trading session.
Boston Scientific Corporation declared the launch of the Captivator™ EMR Device for Endoscopic Mucosal Resection (EMR), a minimally invasive alternative to an esophagectomy, a surgical procedure that removes part of the esophagus in upper gastrointestinal (GI) tract cases. EMR enables staging and removal of precancerous tissue and early esophageal cancer in the upper GI tract during an endoscopic outpatient procedure. The Captivator EMR Device is specifically designed for upper GI EMR and provides physicians with improved visualization, control and easy passage of devices.
A common precursor to esophageal cancer is Barrett’s Esophagus, which is a complication of acid reflux disease that causes abnormal changes to the lining of the esophagus. More than 900,000 people worldwide are diagnosed with Barrett’s Esophagus[1]. Nearly 10 percent of patients with chronic heartburn develop Barrett’s Esophagus and endoscopic administration may assist reduce the potential for an esophagectomy, a more invasive and costly surgery.[
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Women’s Health, and Neuromodulation.
Finally, Media General Inc (NYSE:MEG), ended its last trade with 1.17% gain, and closed at $13.80.
Starboard Value LP (together with its associates, “Starboard”), one of the largest shareholders of Media General, with beneficial ownership of about 4.5% of the outstanding shares of the Company, recently declared that it has delivered a letter to J. Stewart Bryan III, Chairman of Media General’s Board of Directors (the “Board”), and Vincent L. Sadusky, Chief Executive Officer of the Company, with a copy to the Board.
Media General, Inc. (New Media General), formerly known as Mercury New Holdco, Inc., is a multimedia company. The Company operates or services 71 television stations in 48 markets along with the digital media business. It offers consumers and advertisers, entertainment and information, content and distribution on every screen.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
